Zobrazeno 1 - 10
of 15
pro vyhledávání: '"D. Ross Sibson"'
Autor:
Elisabeth J. Shaw, Brian Haylock, David Husband, Daniel du Plessis, D. Ross Sibson, Peter C. Warnke, Carol Walker
Publikováno v:
Analytical Cellular Pathology, Vol 33, Iss 2, Pp 81-94 (2010)
Background: Oligodendroglial tumors with 1p/19q loss are more likely to be chemosensitive and have longer survival than those with intact 1p/19q, but not all respond to chemotherapy, warranting investigation of the biological basis of chemosensitivit
Externí odkaz:
https://doaj.org/article/3956c6b428aa4d5796083b26cd4cde45
Autor:
Dong Liu Barraclough, Susan Sewart, Philip S. Rudland, Balvinder S. Shoker, D. Ross Sibson, Roger Barraclough, Michael P. A. Davies
Publikováno v:
Cellular Oncology, Vol 32, Iss 1-2, Pp 87-99 (2010)
Background: A major challenge of cancer research is to identify key molecules which are responsible for the development of the malignant metastatic phenotype, the major cause of cancer death.
Externí odkaz:
https://doaj.org/article/b0c6663e10d14ed89bb7f1a157e42114
Autor:
Daniel H. Palmer, John R. Arrand, Darren Barton, Wing Kin Syn, Nicholas D. James, Taha Elmetwali, Joseph J. Sacco, Puthen V. Jithesh, Richard M.D. Greensmith, D. Ross Sibson, Jawaher Ansari, Syed A. Hussain, Vijay Aachi, Bryony H. Lloyd
Publikováno v:
International Journal of Oncology
Despite advances in management, bladder cancer remains a major cause of cancer related complications. Characterisation of gene expression patterns in bladder cancer allows the identification of pathways involved in its pathogenesis, and may stimulate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f54b29e9a1881555e2b83678933433b
https://doi.org/10.3892/ijo.2017.3893
https://doi.org/10.3892/ijo.2017.3893
Autor:
John P. Sloane, Balvinder S. Shoker, Michael P.A. Davies, Christine Jarvis, Mussawar Iqbal, D. Ross Sibson
Publikováno v:
The Journal of Pathology. 193:333-338
In normal breast, there is a negative association between expression of oestrogen receptor (ER) and the proliferation marker Ki67, indicating that ER-positive (ER+) cells do not divide, or that the receptor is down-regulated when they do so. However,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4b6e1c1e225ba4cb6c851f459401bff7
https://doi.org/10.1002/1096-9896(2000)9999:9999<::aid-path801>3.0.co
https://doi.org/10.1002/1096-9896(2000)9999:9999<::aid-path801>3.0.co
Publikováno v:
The Journal of Pathology. 188:237-244
As oestrogen is associated with most of the epidemiological risk factors for breast cancer, the number and distribution of oestrogen receptor positive (ER+) cells could have a bearing on the development of the disease. ER+ cells were thus studied in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1a2045f3df4dff941b9074ec8be16e89
https://doi.org/10.1002/(sici)1096-9896(199907)188:3<237::aid-path343>3.0.co
https://doi.org/10.1002/(sici)1096-9896(199907)188:3<237::aid-path343>3.0.co
Publikováno v:
BMC Cancer, Vol 7, Iss 1, p 131 (2007)
BMC CANCER
BMC Cancer
BMC CANCER
BMC Cancer
Background Oestrogen receptor beta (ERβ) modulates ERα activity; wild type ERβ (ERβ1) and its splice variants may therefore impact on hormone responsiveness of breast cancer. ERβ2/ERβcx acts as a dominant negative inhibitor of ERα and expressi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88845cfff3529094accceda55995fe5a
http://www.biomedcentral.com/1471-2407/7/131
http://www.biomedcentral.com/1471-2407/7/131
Publikováno v:
Cancer research. 65(9)
A suppression subtractive cDNA library representing mRNAs expressed at a higher level in the malignant human breast cancer cell line, MCF-7, relative to a benign breast tumor-derived cell line, Huma 123, contained a cDNA, M36, which was expressed in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6dcb2f8fc4bdca44b4cef04d6e23ea65
https://pubmed.ncbi.nlm.nih.gov/15867376
https://pubmed.ncbi.nlm.nih.gov/15867376
Publikováno v:
Breast Cancer Research
Introduction Genetic abnormalities or mutations in premalignant breast lesions may have a role in progression toward malignancy or influence the behaviour of subsequent disease. The A908G (Lys303→Arg) change in the gene encoding oestrogen receptor-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42f2296f1ce41c1a45a43b09e3d697d4
https://doi.org/10.1186/bcr965
https://doi.org/10.1186/bcr965
Autor:
Mussawar Iqbal, Christopher S. Foster, Christine Jarvis, D. Ross Sibson, Balvinder S. Shoker, Michael P.A. Davies
Publikováno v:
Human pathology. 33(7)
Hyperplasia of usual type (HUT) may be an early precursor of breast carcinoma and has been shown to contain molecular and genetic abnormalities previously seen in more advanced breast lesions, such as allelic imbalance (AI) and coexpression of estrog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca429607ad11a751c2166d3620fa2463
https://pubmed.ncbi.nlm.nih.gov/12196923
https://pubmed.ncbi.nlm.nih.gov/12196923
Autor:
Balvinder S. Shoker, Michael P.A. Davies, Christine Jarvis, Joanne Hewlett, John P. Sloane, Elizabeth Anderson, D. Ross Sibson, Robert Clarke
Recently it has been shown that epithelial cell expression of the estrogen receptor (ER) and that of the proliferation-associated marker Ki-67 are almost mutually exclusive in the normal premenopausal human breast but that coexpression frequently occ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f488093ea4feb99ca0d92c85d1d998d8
https://europepmc.org/articles/PMC1866935/
https://europepmc.org/articles/PMC1866935/
